Andersen Ove, Haugaard Steen B, Hansen Birgitte R, Orskov Hans, Andersen Ulrik B, Madsbad Sten, Iversen Johan, Flyvbjerg Allan
Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark.
Scand J Infect Dis. 2004;36(11-12):832-9. doi: 10.1080/00365540410021162.
Growth hormone (GH)-secretion in HIV-lipodystrophy is impaired; however, GH-sensitivity of GH-target tissues remains to be evaluated. We measured overnight fasting concentrations of GH-sensitive insulin-like growth-factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) including GH binding protein (GHBP), a marker of GH-receptor sensitivity, in antiretroviral treated HIV-infected patients with (LIPO) and without lipodystrophy (NONLIPO) and antiretroviral naive HIV-infected patients (NAIVE). Three h GH-suppression tests using oral glucose were undertaken to determine dynamics of GH-secretion. IGF-I and IGFBP-3 were increased in LIPO compared with NONLIPO (p <0.05), but did not differ significantly between NONLIPO and NAIVE. Area under the curve of GH (AUC-GH) during the GH-suppression test was decreased in LIPO compared with NONLIPO (p <0.05). Ratio of limb to trunk fat, which was decreased in LIPO compared to NONLIPO and NAIVE (p <0.001), correlated positively with AUC-GH and rebound-GH (p <0.05). All groups displayed suppression of GH during the suppression test (p <0.05) and all groups, except LIPO, displayed a rebound of GH (p <0.05), which probably is explained by persistently increased plasma glucose in LIPO compared with NONLIPO and NAIVE (p <0.01). GHBP was inversely correlated with AUC-GH (p <0.01). Our data suggest that GH-target tissues in LIPO are at least as GH-sensitive as in HIV-infected patients without lipodystrophy.
在HIV脂肪代谢障碍患者中,生长激素(GH)分泌受损;然而,GH靶组织对GH的敏感性仍有待评估。我们测定了接受抗逆转录病毒治疗的合并脂肪代谢障碍(LIPO)和未合并脂肪代谢障碍(NONLIPO)的HIV感染患者以及未接受过抗逆转录病毒治疗的HIV感染患者(NAIVE)过夜空腹时GH敏感的胰岛素样生长因子-I(IGF-I)和IGF结合蛋白-3(IGFBP-3)的浓度,其中包括GH结合蛋白(GHBP),它是GH受体敏感性的一个标志物。采用口服葡萄糖进行了3小时GH抑制试验以确定GH分泌的动态变化。与NONLIPO相比,LIPO患者的IGF-I和IGFBP-3升高(p<0.05),但NONLIPO和NAIVE患者之间无显著差异。与NONLIPO相比,LIPO患者在GH抑制试验期间GH的曲线下面积(AUC-GH)降低(p<0.05)。与NONLIPO和NAIVE相比,LIPO患者的肢体与躯干脂肪比例降低(p<0.001),该比例与AUC-GH和GH反弹呈正相关(p<0.05)。所有组在抑制试验期间GH均受到抑制(p<0.05),除LIPO组外所有组均出现GH反弹(p<0.05),这可能是因为与NONLIPO和NAIVE相比,LIPO患者的血浆葡萄糖持续升高(p<0.01)。GHBP与AUC-GH呈负相关(p<0.01)。我们的数据表明,LIPO患者的GH靶组织对GH的敏感性至少与未合并脂肪代谢障碍的HIV感染患者相同。